# US 2024/0003872 A1 · Methods for assaying and measuring the efficacy of anti-nausea compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003872 A1
- Document ID: US20240003872A1
- Status: Published application
- Kind: A1
- Application number: 18/037,028
- Filed: 2021-11-15
- Published: 2024-01-04
- Earliest claimed: 2020-11-15
- Assignees: Aphios Corporation
- Applicants: CASTOR, Trevor, p .
- Inventors: Trevor Percival Castor
- Web page: https://patentgrep.com/patent/US20240003872A1

## CPC

- G01N 33/5061: {Muscle cells}
- G01N 33/942: {Serotonin, i.e. 5-hydroxy-tryptamine}
- G01N 33/5082: {Supracellular entities, e.g. tissue, organisms}
- C12N 5/0661: {Smooth muscle cells}
- C12N 2503/02: Drug screening
- G01N 2333/70571: for neuromediators, e.g. serotonin receptor, dopamine receptor
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention is for methods to quantify the inhibition of 5-HT induced contraction of human intestinal smooth muscle and an assay to measure the effects of compounds on nausea, irritable bowel syndrome and irritable bowel disease. This invention can be used to measure the incidence and severity of nausea, and can be used as quality control assay for developing and releasing medications for controlling nausea and emesis.

## Claims

### Claim 1

A method or assay for measuring the effectiveness of test compounds for blocking or inhibiting 5-HT induced contraction of human intestinal smooth muscle cells (HISMC), comprising the steps of:
(a) providing an in vitro sample of human intestinal smooth muscle cells (HISMC) in a cell culture growth medium for assay;
(b) providing a sample test compound, with 5-HT3 antagonist properties, which inhibits contraction of human intestinal smooth muscle cells ((HISMC);
(c) mixing or combining a selected amount of the test compound in a predetermined concentration with the in vitro sample of human intestinal smooth muscle cells ((HISMC);
(d) measuring the contractile responsiveness of the HISMC sample to the test compound by measuring cell contraction vs time for a predetermined test period;
(e) repeating the measuring using different concentrations of the test compound; and
(f) determining, based on the measured data, the efficacy of the test compound to inhibit 5-HT induced contractions of the human intestinal smooth muscle cells (HISMC).

### Claim 2 (depends on 1)

The method of claim 1, further including the step of providing a control sample, wherein the human intestinal smooth muscle cells (HISMC) are left untreated.

### Claim 3 (depends on 1)

The method of claim 1, wherein the human intestinal smooth muscle cells (HISMC) are cultured in collagen matrices in a gel formulation.

### Claim 4 (depends on 1)

The method of claim 1, wherein the test compound includes gingerol or ginger-based compounds.

### Claim 5 (depends on 1)

The method of claim 1, wherein the test compound includes Zindol.

### Claim 6 (depends on 5)

The method of claim 5, wherein the test compound includes Z-oil.

### Claim 7 (depends on 1)

The method of claim 1, wherein the test compound includes Ondansetron.

### Claim 8 (depends on 1)

The method of claim 1, wherein the test compound includes Aprepitant.

### Claim 9 (depends on 1)

The method of claim 1, wherein the test compound includes a DMSO solvent.

### Claim 10 (depends on 1)

The method of claim 1, wherein the assay of performed with bovine turbinate cells (BTC).

### Claim 11 (depends on 1)

The method of claim 1, wherein the efficacy of the test compound is determined for treating post-chemotherapy nausea.

### Claim 12 (depends on 1)

The method of claim 1, wherein the efficacy of the test compound is determined for treating post-operative nausea.

### Claim 13 (depends on 1)

The method of claim 1, wherein the efficacy of the test compound is determined for treating irritable bowel syndrome and irritable bowel disease.

### Claim 14

A kit for measuring the effectiveness of test compounds for blocking or inhibiting 5-HT induced contraction of human intestinal smooth muscle cells (HISMC), comprising the steps of:
(g) providing an in vitro sample of human intestinal smooth muscle cells (HISMC) in a cell culture growth medium for assay;
(h) providing a sample test compound, with 5-HT3 antagonist properties, which inhibits contraction of human intestinal smooth muscle cells ((HISMC);
(i) mixing or combining a selected amount of the test compound in a predetermined concentration with the in vitro sample of human intestinal smooth muscle cells ((HISMC);
(j) measuring the contractile responsiveness of the HISMC sample to the test compound by measuring cell contraction vs time for a predetermined test period;
(k) repeating the measuring using different concentrations of the test compound; and
(l) determining, based on the measured data, the efficacy of the test compound to inhibit 5-HT induced contractions of the human intestinal smooth muscle cells (HISMC).
